Effectiveness of Nirmatrelvir-Ritonavir for the Prevention of COVID-19-Related Hospitalization and Mortality: A Systematic Literature Review.

8 Prespecified secondary end point results showed a nominally significant 62% decrease in COVID-19–related medical visits per day across all patients, relative to placebo in a subgroup analysis. 9 However, questions still remain about the clinical relevance of these results for the treatment of contemporary patients in the real-world setting, given that the EPIC-HR trial was conducted in unvaccinated adults without a history of prior infection during a period when the Delta variant was the predominant one.

also in 7,732 other papers